CL2013000034A1 - Composicion farmaceutica que comprende un compuesto derivado de ester 3-[4-(aril)-piperazin-1-il]-1-fenil-propilico de acido carbamico y un portador, util para prevenir o tratar nefropatia diabetica, neuropatia diabetica, complicaciones vasculares diabeticas, hiperlipidemia, arteriopatia coronaria e inflamacion. - Google Patents
Composicion farmaceutica que comprende un compuesto derivado de ester 3-[4-(aril)-piperazin-1-il]-1-fenil-propilico de acido carbamico y un portador, util para prevenir o tratar nefropatia diabetica, neuropatia diabetica, complicaciones vasculares diabeticas, hiperlipidemia, arteriopatia coronaria e inflamacion.Info
- Publication number
- CL2013000034A1 CL2013000034A1 CL2013000034A CL2013000034A CL2013000034A1 CL 2013000034 A1 CL2013000034 A1 CL 2013000034A1 CL 2013000034 A CL2013000034 A CL 2013000034A CL 2013000034 A CL2013000034 A CL 2013000034A CL 2013000034 A1 CL2013000034 A1 CL 2013000034A1
- Authority
- CL
- Chile
- Prior art keywords
- hyperlipidemia
- piperazin
- inflammation
- aryl
- phenyl
- Prior art date
Links
- 208000007342 Diabetic Nephropathies Diseases 0.000 title 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 title 1
- 208000031226 Hyperlipidaemia Diseases 0.000 title 1
- 206010003230 arteritis Diseases 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 208000029078 coronary artery disease Diseases 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 208000033679 diabetic kidney disease Diseases 0.000 title 1
- 150000002148 esters Chemical class 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002792 vascular Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/66—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100065950A KR101810975B1 (ko) | 2010-07-08 | 2010-07-08 | 카바모일옥시 아릴알칸노일 아릴피페라진계 화합물을 포함하는 약학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013000034A1 true CL2013000034A1 (es) | 2013-10-04 |
Family
ID=45441670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013000034A CL2013000034A1 (es) | 2010-07-08 | 2013-01-04 | Composicion farmaceutica que comprende un compuesto derivado de ester 3-[4-(aril)-piperazin-1-il]-1-fenil-propilico de acido carbamico y un portador, util para prevenir o tratar nefropatia diabetica, neuropatia diabetica, complicaciones vasculares diabeticas, hiperlipidemia, arteriopatia coronaria e inflamacion. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8648083B2 (es) |
| EP (1) | EP2590650A4 (es) |
| JP (3) | JP5985472B2 (es) |
| KR (1) | KR101810975B1 (es) |
| CN (1) | CN103096892B (es) |
| AU (1) | AU2011274665B2 (es) |
| BR (1) | BR112013000532A2 (es) |
| CA (1) | CA2803580C (es) |
| CL (1) | CL2013000034A1 (es) |
| HK (1) | HK1181305A1 (es) |
| MX (1) | MX2012015015A (es) |
| RU (1) | RU2630619C2 (es) |
| WO (1) | WO2012005536A2 (es) |
| ZA (1) | ZA201209631B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008140198A1 (en) * | 2007-05-14 | 2008-11-20 | Sk Holdings Co., Ltd. | Novel carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound |
| KR101810975B1 (ko) | 2010-07-08 | 2017-12-20 | 에스케이바이오팜 주식회사 | 카바모일옥시 아릴알칸노일 아릴피페라진계 화합물을 포함하는 약학적 조성물 |
| RU2702117C1 (ru) * | 2016-01-27 | 2019-10-04 | Бориюнг Фармасьютикал Ко., Лтд. | Фармацевтическая композиция для предупреждения или лечения диабетической нефропатии |
| BR112020013140A2 (pt) * | 2017-12-28 | 2020-12-01 | Reviva Pharmaceuticals, Inc. | método para tratar fibrose pulmonar em um indivíduo. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001261269A1 (en) | 2000-06-14 | 2001-12-24 | Warner Lambert Company | 1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase |
| ZA200803636B (en) * | 2005-10-31 | 2009-10-28 | Biolipox Ab | Triazole compounds as lipoxygenase inhibitors |
| KR20080040393A (ko) | 2006-11-03 | 2008-05-08 | 정수환 | 소스 라우팅 기반의 이동 애드 혹 네트워크에서 안전한데이터 전송 방법 |
| WO2008140198A1 (en) | 2007-05-14 | 2008-11-20 | Sk Holdings Co., Ltd. | Novel carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound |
| JP2011506294A (ja) | 2007-12-05 | 2011-03-03 | アストラゼネカ アクチボラグ | 抗肥満薬としてのピペラジン |
| WO2011093776A1 (en) * | 2010-01-28 | 2011-08-04 | Ge Healthcare Bio-Sciences Ab | Column for liquid chromatography |
| KR101810975B1 (ko) | 2010-07-08 | 2017-12-20 | 에스케이바이오팜 주식회사 | 카바모일옥시 아릴알칸노일 아릴피페라진계 화합물을 포함하는 약학적 조성물 |
-
2010
- 2010-07-08 KR KR1020100065950A patent/KR101810975B1/ko active IP Right Grant
-
2011
- 2011-07-08 WO PCT/KR2011/004996 patent/WO2012005536A2/en active Application Filing
- 2011-07-08 JP JP2013518279A patent/JP5985472B2/ja active Active
- 2011-07-08 BR BR112013000532A patent/BR112013000532A2/pt not_active Application Discontinuation
- 2011-07-08 RU RU2013102958A patent/RU2630619C2/ru active
- 2011-07-08 MX MX2012015015A patent/MX2012015015A/es active IP Right Grant
- 2011-07-08 EP EP11803822.3A patent/EP2590650A4/en active Pending
- 2011-07-08 AU AU2011274665A patent/AU2011274665B2/en not_active Ceased
- 2011-07-08 US US13/805,098 patent/US8648083B2/en active Active
- 2011-07-08 CA CA2803580A patent/CA2803580C/en active Active
- 2011-07-08 CN CN201180043088.XA patent/CN103096892B/zh active Active
-
2012
- 2012-12-19 ZA ZA2012/09631A patent/ZA201209631B/en unknown
-
2013
- 2013-01-04 CL CL2013000034A patent/CL2013000034A1/es unknown
- 2013-07-23 HK HK13108598.4A patent/HK1181305A1/xx unknown
-
2014
- 2014-01-24 US US14/163,836 patent/US9238633B2/en active Active
-
2016
- 2016-04-15 JP JP2016082519A patent/JP2016193901A/ja active Pending
-
2017
- 2017-11-06 JP JP2017214151A patent/JP6562522B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012005536A2 (en) | 2012-01-12 |
| US8648083B2 (en) | 2014-02-11 |
| ZA201209631B (en) | 2014-03-26 |
| US20130131081A1 (en) | 2013-05-23 |
| BR112013000532A2 (pt) | 2016-06-07 |
| CN103096892B (zh) | 2015-08-12 |
| AU2011274665A1 (en) | 2013-01-17 |
| JP5985472B2 (ja) | 2016-09-06 |
| EP2590650A2 (en) | 2013-05-15 |
| JP2016193901A (ja) | 2016-11-17 |
| RU2013102958A (ru) | 2014-08-20 |
| US9238633B2 (en) | 2016-01-19 |
| JP2013536161A (ja) | 2013-09-19 |
| MX2012015015A (es) | 2013-02-07 |
| EP2590650A4 (en) | 2014-01-08 |
| AU2011274665B2 (en) | 2015-01-15 |
| KR101810975B1 (ko) | 2017-12-20 |
| CA2803580C (en) | 2018-05-01 |
| KR20120005286A (ko) | 2012-01-16 |
| US20140243352A1 (en) | 2014-08-28 |
| RU2630619C2 (ru) | 2017-09-11 |
| WO2012005536A3 (en) | 2012-04-05 |
| JP2018058855A (ja) | 2018-04-12 |
| JP6562522B2 (ja) | 2019-08-21 |
| CA2803580A1 (en) | 2012-01-12 |
| CN103096892A (zh) | 2013-05-08 |
| HK1181305A1 (en) | 2013-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013000034A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de ester 3-[4-(aril)-piperazin-1-il]-1-fenil-propilico de acido carbamico y un portador, util para prevenir o tratar nefropatia diabetica, neuropatia diabetica, complicaciones vasculares diabeticas, hiperlipidemia, arteriopatia coronaria e inflamacion. | |
| CL2014000645A1 (es) | Composicion farmaceutica que comprende a) un ciclopolisacarido tal como una ciclodextrina y b) un compuesto derivado de acido hidroxamico y sus sales, util para tratar una enfermedad neoplasica o una enfermedad inmunitaria. | |
| CL2015000188A1 (es) | Composición herbicida que comprende ácido 4-amino-3-cloro-5-fluoro-6-(4-cloro-2-fluoro-3-metoxifenilo) piridina-2-carboxílico o un derivado del mismo y al menos un compuesto seleccionado de ciertas sulfonilureas; y método para controlar vegetación indeseable. | |
| CL2013002114A1 (es) | Compuestos de esteres de arilalquilo de 4 - amino - 6 - (fenil sustituido) picolinatos y 6 - amino- 2 - (fenil sustituido) - 4 - pirimidincarboxilatos; composicion herbicida que comprende dichos compuestos; metodo para el control de vegetacion indeseable. | |
| AR083411A1 (es) | Composicion que controla las plagas y metodo para controlarlas | |
| CL2014000357A1 (es) | Compuesto acido (3s)-3-[4-[[5-[(8-metoxi-3,4-dihidro-2h-quinolin-1-il)metil]-2-tienil]metoxi]fenil]hex-4-inoico; metodo para prepararlo; composicion farmaceutica que lo comprende; compuesto intermediario; y su uso para tratar diabetes. | |
| BR112015001098A2 (pt) | composto, composição farmacêutica e método para o tratamento de uma condição de doença. | |
| BR112012004333A2 (pt) | composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio. | |
| BRPI0915382A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio. | |
| CL2014000012A1 (es) | Composicion fungicida que comprende derivados de metilpiridina y al menos un fungicida seleccionado del grupo que esta compuesto de bixafen, fluxapiroxad, penflufen, isopirazam, fluopiram, ametoctradin, fenpirazamina y sedaxan; metodo para controlar enfermedades de plantas. | |
| BRPI1012642A2 (pt) | formulação de insulina e método para o tratamento de um indivíduo diabético. | |
| BR112014004590A2 (pt) | processo para efetuar uma oxidação em um suprimento passível de aspersão; e processo para fazer ácido 2,5-furanodicarboxílico a partir de frutose, glicose ou uma combinação de frutos e glicose | |
| BRPI0920794A2 (pt) | método para produzir um éster de ácido carbâmico n-substituído, e, composição para transferência e armazenamento de um o-ar éster de ácido carbâmico n-substituído. | |
| BRPI0924997A2 (pt) | Método para preparar um composto de éster do ácido aril-2-tetrazoil etil carbâmico. | |
| BRPI0821676A2 (pt) | Composto, composição farmacêutica, e, processo para a preparação dos compostos. | |
| BR112012002582A2 (pt) | método para operar uma lavadora, e, lavadora. | |
| CL2012003009A1 (es) | Acido3-(((3-butil-3-etil-(metiloxi)-1-1-dioxido-5-fenil-2,3,4,5-tetrahidro-1,4benxotiazepin-8-il)-metil)-amino)-pentanodioco; composicion farmaceutica que lo comprende; y su uso en un tastorno metabolico. pct. | |
| DK2493533T3 (da) | Automatisk applikator til flydende farmaceutiske præparater, fortrinsvist særligt til insulin | |
| CL2007002424A1 (es) | Compuestos derivados de isoxazolidina; composicion farmaceutica que comprende a dicho compuesto, util para el tratamiento de trastornos asociados con hiperproliferacion como cancer. | |
| BRPI1016132A2 (pt) | composição, formulação farmacêutica, método para fabricar uma formulação farmacêutica estável. | |
| BRPI0919578A2 (pt) | produto, composto, e processos para o isolamento de um composto e para a preparação de dronedarona ou um sal do mesmo, de uma formulação farmacêutica compreendendo dronedarona ou um sinal do mesmo e de um intermediário de dronedarona ou um sal do mesmo | |
| BR112014032510A2 (pt) | composto, composição farmacêutica, método para tratar ou prevenir uma doença ou desordem, e, uso de um composto. | |
| BR112013031712A2 (pt) | composto, composição farmacêutica, métodos para preparar um composto e para o tratamento de um distúrbio ou uma doença. | |
| BR112013001111A2 (pt) | processo para a produção do composto da fórmula 1, processo para a produção de um composto da fórmula a, processo para a produção dos compostos da fórmula d, composto da fórmula e, composto da fórmula f e novos compostos | |
| BR112012002611A2 (pt) | método para operar uma lavadora, e, lavadora. |